58-37-4 - Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.
58-37-4. Schedules of controlled substances -- Schedules I through V -- Findingsrequired -- Specific substances included in schedules.
(1) There are established five schedules of controlled substances known as Schedules I,II, III, IV, and V which shall consist of substances listed in this section.
(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances bythe official name, common or usual name, chemical name, or brand name designated:
(a) Schedule I:
(i) Unless specifically excepted or unless listed in another schedule, any of the followingopiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenthe existence of the isomers, esters, ethers, and salts is possible within the specific chemicaldesignation:
(A) Acetyl-alpha-methylfentanyl(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(B) Acetylmethadol;
(C) Allylprodine;
(D) Alphacetylmethadol, except levo-alphacetylmethadol also known aslevo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
(E) Alphameprodine;
(F) Alphamethadol;
(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(I) Benzethidine;
(J) Betacetylmethadol;
(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
(M) Betameprodine;
(N) Betamethadol;
(O) Betaprodine;
(P) Clonitazene;
(Q) Dextromoramide;
(R) Diampromide;
(S) Diethylthiambutene;
(T) Difenoxin;
(U) Dimenoxadol;
(V) Dimepheptanol;
(W) Dimethylthiambutene;
(X) Dioxaphetyl butyrate;
(Y) Dipipanone;
(Z) Ethylmethylthiambutene;
(AA) Etonitazene;
(BB) Etoxeridine;
(CC) Furethidine;
(DD) Hydroxypethidine;
(EE) Ketobemidone;
(FF) Levomoramide;
(GG) Levophenacylmorphan;
(HH) Morpheridine;
(II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(JJ) Noracymethadol;
(KK) Norlevorphanol;
(LL) Normethadone;
(MM) Norpipanone;
(NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]propanamide;
(OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(PP) Phenadoxone;
(QQ) Phenampromide;
(RR) Phenomorphan;
(SS) Phenoperidine;
(TT) Piritramide;
(UU) Proheptazine;
(VV) Properidine;
(WW) Propiram;
(XX) Racemoramide;
(YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
(ZZ) Tilidine;
(AAA) Trimeperidine;
(BBB) 3-methylfentanyl, including the optical and geometric isomers(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
(CCC) 3-methylthiofentanyl(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
(ii) Unless specifically excepted or unless listed in another schedule, any of the followingopium derivatives, their salts, isomers, and salts of isomers when the existence of the salts,isomers, and salts of isomers is possible within the specific chemical designation:
(A) Acetorphine;
(B) Acetyldihydrocodeine;
(C) Benzylmorphine;
(D) Codeine methylbromide;
(E) Codeine-N-Oxide;
(F) Cyprenorphine;
(G) Desomorphine;
(H) Dihydromorphine;
(I) Drotebanol;
(J) Etorphine (except hydrochloride salt);
(K) Heroin;
(L) Hydromorphinol;
(M) Methyldesorphine;
(N) Methylhydromorphine;
(O) Morphine methylbromide;
(P) Morphine methylsulfonate;
(Q) Morphine-N-Oxide;
(R) Myrophine;
(S) Nicocodeine;
(T) Nicomorphine;
(U) Normorphine;
(V) Pholcodine; and
(W) Thebacon.
(iii) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following hallucinogenicsubstances, or which contains any of their salts, isomers, and salts of isomers when the existenceof the salts, isomers, and salts of isomers is possible within the specific chemical designation; asused in this Subsection (2)(iii) only, "isomer" includes the optical, position, and geometricisomers:
(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;.-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;
(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
(C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
(D) 2,5-dimethoxyamphetamine, some trade or other names:2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
(F) 4-methoxyamphetamine, some trade or other names:4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
(G) 5-methoxy-3,4-methylenedioxyamphetamine;
(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
(I) 3,4-methylenedioxy amphetamine;
(J) 3,4-methylenedioxymethamphetamine (MDMA);
(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known asN-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
(M) 3,4,5-trimethoxy amphetamine;
(N) Bufotenine, some trade and other names:3-(.-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
(P) Dimethyltryptamine, some trade or other names: DMT;
(Q) Ibogaine, some trade and other names:7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
[5,4-b] indole; Tabernanthe iboga;
(R) Lysergic acid diethylamide;
(S) Marijuana;
(T) Mescaline;
(U) Parahexyl, some trade or other names:3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
(V) Peyote, meaning all parts of the plant presently classified botanically as Lophophorawilliamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of suchplant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant,its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
(W) N-ethyl-3-piperidyl benzilate;
(X) N-methyl-3-piperidyl benzilate;
(Y) Psilocybin;
(Z) Psilocyn;
(AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in theplant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, andtheir isomers with similar chemical structure and pharmacological activity such as the following:.1 cis or trans tetrahydrocannabinol, and their optical isomers .6 cis or transtetrahydrocannabinol, and their optical isomers .3,4 cis or trans tetrahydrocannabinol, and itsoptical isomers, and since nomenclature of these substances is not internationally standardized,compounds of these structures, regardless of numerical designation of atomic positions covered;
(BB) Ethylamine analog of phencyclidine, some trade or other names:N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
(CC) Pyrrolidine analog of phencyclidine, some trade or other names:1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
(DD) Thiophene analog of phencyclidine, some trade or other names:1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
(iv) Unless specifically excepted or unless listed in another schedule, any materialcompound, mixture, or preparation which contains any quantity of the following substanceshaving a depressant effect on the central nervous system, including its salts, isomers, and salts ofisomers when the existence of the salts, isomers, and salts of isomers is possible within thespecific chemical designation:
(A) Mecloqualone; and
(B) Methaqualone.
(v) Any material, compound, mixture, or preparation containing any quantity of thefollowing substances having a stimulant effect on the central nervous system, including theirsalts, isomers, and salts of isomers:
(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or4,5-dihydro-5-phenyl-2-oxazolamine;
(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
(C) Fenethylline;
(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts ofoptical isomers;
(E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
(F) N-ethylamphetamine; and
(G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine;N,N-alpha-trimethylphenethylamine.
(vi) Any material, compound, mixture, or preparation which contains any quantity of thefollowing substances, including their optical isomers, salts, and salts of isomers, subject totemporary emergency scheduling:
(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
(vii) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
(b) Schedule II:
(i) Unless specifically excepted or unless listed in another schedule, any of the followingsubstances whether produced directly or indirectly by extraction from substances of vegetableorigin, or independently by means of chemical synthesis, or by a combination of extraction andchemical synthesis:
(A) Opium and opiate, and any salt, compound, derivative, or preparation of opium oropiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,and their respective salts, but including:
(I) Raw opium;
(II) Opium extracts;
(III) Opium fluid;
(IV) Powdered opium;
(V) Granulated opium;
(VI) Tincture of opium;
(VII) Codeine;
(VIII) Ethylmorphine;
(IX) Etorphine hydrochloride;
(X) Hydrocodone;
(XI) Hydromorphone;
(XII) Metopon;
(XIII) Morphine;
(XIV) Oxycodone;
(XV) Oxymorphone; and
(XVI) Thebaine;
(B) Any salt, compound, derivative, or preparation which is chemically equivalent oridentical with any of the substances referred to in Subsection (2)(b)(i)(A), except that thesesubstances may not include the isoquinoline alkaloids of opium;
(C) Opium poppy and poppy straw;
(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
any salt, compound, derivative, or preparation which is chemically equivalent or identical withany of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, andsalts of isomers and derivatives, whether derived from the coca plant or synthetically produced,except the substances may not include decocainized coca leaves or extraction of coca leaves,which extractions do not contain cocaine or ecgonine; and
(E) Concentrate of poppy straw, which means the crude extract of poppy straw in eitherliquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
(ii) Unless specifically excepted or unless listed in another schedule, any of the followingopiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenthe existence of the isomers, esters, ethers, and salts is possible within the specific chemicaldesignation, except dextrorphan and levopropoxyphene:
(A) Alfentanil;
(B) Alphaprodine;
(C) Anileridine;
(D) Bezitramide;
(E) Bulk dextropropoxyphene (nondosage forms);
(F) Carfentanil;
(G) Dihydrocodeine;
(H) Diphenoxylate;
(I) Fentanyl;
(J) Isomethadone;
(K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,levomethadyl acetate, or LAAM;
(L) Levomethorphan;
(M) Levorphanol;
(N) Metazocine;
(O) Methadone;
(P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylicacid;
(R) Pethidine (meperidine);
(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(V) Phenazocine;
(W) Piminodine;
(X) Racemethorphan;
(Y) Racemorphan;
(Z) Remifentanil; and
(AA) Sufentanil.
(iii) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substanceshaving a stimulant effect on the central nervous system:
(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(B) Methamphetamine, its salts, isomers, and salts of its isomers;
(C) Phenmetrazine and its salts; and
(D) Methylphenidate.
(iv) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substanceshaving a depressant effect on the central nervous system, including its salts, isomers, and salts ofisomers when the existence of the salts, isomers, and salts of isomers is possible within thespecific chemical designation:
(A) Amobarbital;
(B) Glutethimide;
(C) Pentobarbital;
(D) Phencyclidine;
(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and1-piperidinocyclohexanecarbonitrile (PCC); and
(F) Secobarbital.
(v) (A) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of Phenylacetone.
(B) Some of these substances may be known by trade or other names:phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
(vi) Nabilone, another name for nabilone:(.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
(c) Schedule III:
(i) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substanceshaving a stimulant effect on the central nervous system, including its salts, isomers whetheroptical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,and salts of isomers is possible within the specific chemical designation:
(A) Those compounds, mixtures, or preparations in dosage unit form containing anystimulant substances listed in Schedule II, which compounds, mixtures, or preparations werelisted on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Codeof Federal Regulations, and any other drug of the quantitive composition shown in that list forthose drugs or which is the same except that it contains a lesser quantity of controlled substances;
(B) Benzphetamine;
(C) Chlorphentermine;
(D) Clortermine; and
(E) Phendimetrazine.
(ii) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substanceshaving a depressant effect on the central nervous system:
(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,pentobarbital, or any salt of any of them, and one or more other active medicinal ingredientswhich are not listed in any schedule;
(B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital,or any salt of any of these drugs which is approved by the Food and Drug Administration formarketing only as a suppository;
(C) Any substance which contains any quantity of a derivative of barbituric acid or anysalt of any of them;
(D) Chlorhexadol;
(E) Buprenorphine;
(F) Any drug product containing gamma hydroxybutyric acid, including its salts,isomers, and salts of isomers, for which an application is approved under the federal Food, Drug,and Cosmetic Act, Section 505;
(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: .-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
(H) Lysergic acid;
(I) Lysergic acid amide;
(J) Methyprylon;
(K) Sulfondiethylmethane;
(L) Sulfonethylmethane;
(M) Sulfonmethane; and
(N) Tiletamine and zolazepam or any of their salts, some trade or other names for atiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,flupyrazapon.
(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in aU.S. Food and Drug Administration approved drug product, some other names for dronabinol:(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or(-)-delta-9-(trans)-tetrahydrocannabinol.
(iv) Nalorphine.
(v) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation containing limited quantities of any of the following narcoticdrugs, or their salts calculated as the free anhydrous base or alkaloid:
(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid ofopium;
(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90milligrams per dosage unit, with one or more active non-narcotic ingredients in recognizedtherapeutic amounts;
(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not morethan 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloidof opium;
(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not morethan 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients inrecognized therapeutic amounts;
(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90milligrams per dosage unit, with one or more active non-narcotic ingredients in recognizedtherapeutic amounts;
(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or notmore than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients inrecognized therapeutic amounts; and
(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams withone or more active, non-narcotic ingredients in recognized therapeutic amounts.
(vi) Unless specifically excepted or unless listed in another schedule, anabolic steroidsincluding any of the following or any isomer, ester, salt, or derivative of the following thatpromotes muscle growth:
(A) Boldenone;
(B) Chlorotestosterone (4-chlortestosterone);
(C) Clostebol;
(D) Dehydrochlormethyltestosterone;
(E) Dihydrotestosterone (4-dihydrotestosterone);
(F) Drostanolone;
(G) Ethylestrenol;
(H) Fluoxymesterone;
(I) Formebulone (formebolone);
(J) Mesterolone;
(K) Methandienone;
(L) Methandranone;
(M) Methandriol;
(N) Methandrostenolone;
(O) Methenolone;
(P) Methyltestosterone;
(Q) Mibolerone;
(R) Nandrolone;
(S) Norethandrolone;
(T) Oxandrolone;
(U) Oxymesterone;
(V) Oxymetholone;
(W) Stanolone;
(X) Stanozolol;
(Y) Testolactone;
(Z) Testosterone; and
(AA) Trenbolone.
(vii) Anabolic steroids expressly intended for administration through implants to cattle orother nonhuman species, and approved by the Secretary of Health and Human Services for use,may not be classified as a controlled substance.
(d) Schedule IV:
(i) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation containing not more than 1 milligram of difenoxin and notless than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
(ii) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substances,
including its salts, isomers, and salts of isomers when the existence of the salts, isomers, andsalts of isomers is possible within the specific chemical designation:
(A) Alprazolam;
(B) Barbital;
(C) Bromazepam;
(D) Butorphanol;
(E) Camazepam;
(F) Carisoprodol;
(G) Chloral betaine;
(H) Chloral hydrate;
(I) Chlordiazepoxide;
(J) Clobazam;
(K) Clonazepam;
(L) Clorazepate;
(M) Clotiazepam;
(N) Cloxazolam;
(O) Delorazepam;
(P) Diazepam;
(Q) Dichloralphenazone;
(R) Estazolam;
(S) Ethchlorvynol;
(T) Ethinamate;
(U) Ethyl loflazepate;
(V) Fludiazepam;
(W) Flunitrazepam;
(X) Flurazepam;
(Y) Halazepam;
(Z) Haloxazolam;
(AA) Ketazolam;
(BB) Loprazolam;
(CC) Lorazepam;
(DD) Lormetazepam;
(EE) Mebutamate;
(FF) Medazepam;
(GG) Meprobamate;
(HH) Methohexital;
(II) Methylphenobarbital (mephobarbital);
(JJ) Midazolam;
(KK) Nimetazepam;
(LL) Nitrazepam;
(MM) Nordiazepam;
(NN) Oxazepam;
(OO) Oxazolam;
(PP) Paraldehyde;
(QQ) Pentazocine;
(RR) Petrichloral;
(SS) Phenobarbital;
(TT) Pinazepam;
(UU) Prazepam;
(VV) Quazepam;
(WW) Temazepam;
(XX) Tetrazepam;
(YY) Triazolam;
(ZZ) Zaleplon; and
(AAA) Zolpidem.
(iii) Any material, compound, mixture, or preparation of fenfluramine which containsany quantity of the following substances, including its salts, isomers whether optical, position, orgeometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomersis possible.
(iv) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substanceshaving a stimulant effect on the central nervous system, including its salts, isomers whetheroptical, position, or geometric isomers, and salts of the isomers when the existence of the salts,isomers, and salts of isomers is possible within the specific chemical designation:
(A) Cathine ((+)-norpseudoephedrine);
(B) Diethylpropion;
(C) Fencamfamine;
(D) Fenproprex;
(E) Mazindol;
(F) Mefenorex;
(G) Modafinil;
(H) Pemoline, including organometallic complexes and chelates thereof;
(I) Phentermine;
(J) Pipradrol;
(K) Sibutramine; and
(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
(v) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of dextropropoxyphene(alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
(e) Schedule V: Any compound, mixture, or preparation containing any of the followinglimited quantities of narcotic drugs, or their salts calculated as the free anhydrous base oralkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficientproportion to confer upon the compound, mixture, or preparation valuable medicinal qualitiesother than those possessed by the narcotic drug alone:
(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms ofatropine sulfate per dosage unit;
(v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms ofatropine sulfate per dosage unit; and
(vii) unless specifically exempted or excluded or unless listed in another schedule, anymaterial, compound, mixture, or preparation which contains Pyrovalerone having a stimulanteffect on the central nervous system, including its salts, isomers, and salts of isomers.
Amended by Chapter 106, 2010 General Session